The drug shows a higher affinity for hPRLR. The dose is the same in phase II, so they believe the dose is sufficient too. Macaques have a much shorter hair cycle, and that could affect how long it takes to respond. It's possible that miniaturization can only be reversed during early anagen.HairLossTalk.com community is so depressive... So, what people do not see here, apart from the evident regrowth in a clinical phase whose main objective is not to assess effectivenes and dosage, but rather check efficacy and safety, is that it's being proven that the PRLR is really linked to Androgenetic Alopecia.
It might be that the antibody shows higher affinity to the monekys PRLR than for humans. It might be that the dosage is too low for humans. It might be a matter of the timespan of hair cycles... Only for HMI there is a lot to be researched.
But more importantly, this opens new research lines for new products based on silencing the PRLR, because, let's be clear, a monoclonal antibody is not very likely to be very marketable as a treatment for a (for many) cosmetical issue.
It's also possible that humans have a redundant mechanism that is unaffected by the PRLR